Market Overview

Gene Munster: Tesla Investors Will Be Rewarded After A Longer-Than-Expected Shift To Autonomy

Gene Munster: Tesla Investors Will Be Rewarded After A Longer-Than-Expected Shift To Autonomy
Related TSLA
Bulls & Bears Of The Week: Cisco, Coca-Cola, IBM, Tesla And More
Analysis: Why New York's Amazon Bungle Is A Big Win For Freight Alley
Tesla: The Importance Of A Chinese Gigafactory (Seeking Alpha)

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk sets ambitious schedules for futuristic tech rollouts, but the firm’s Wednesday earnings report justified skeptics' concerns. 

Apart from Model 3 delays, Tesla reported a 27-percent earnings-per-share miss, a significant quarter-over-quarter gross margins reduction and the firm’s first-ever investment scaleback to limit cash burn.

“Tonight’s Tesla results once again add further evidence that the shift to EV [electric vehicles], autonomy and renewable energy will take longer than we expect,” Loup Ventures managing partner Gene Munster said in a Wednesday night note. “That said, we believe investors will be rewarded for their patience as Tesla works through the production difficulties of the Model 3.”

The Big Picture

Production bottlenecks limited Model 3 deliveries to just 222 this quarter.

Munster told Benzinga the miss was likely a fixable factor of complications in facility construction, but accordingly cut December delivery forecasts from 5,400 to 2,500 units, March deliveries from 35,000 to 10,700, and 2018 deliveries from 200,660 to 190,582.

The expected delays correspond with a profitability pushback from December 2019 to September 2020 — a feat to be achieved by the concurrent activation of Level 5 autonomy and a 2019 Model 3 production ramp — and a cut to 2023 gross margin estimates from 30.5 percent to 28 percent.

But the setbacks don’t affect Munster’s bullish thesis.

“The last wave to the Tesla story generally will begin gaining traction in 2020 and continue through 2030 as the company begins to inch towards its mission statement of accelerating the global adoption or renewable energy driven by Tesla solar and storage solutions,” he said. 

A Decided Leader

While assured by Tesla’s energy opportunities, Munster is no less optimistic about the firm’s auto prospects. In fact, he predicts Tesla to be one of three to five automakers dominating the industry in 10 years, as its electric vehicle and autonomy projects are considered to be unrivaled.

“Putting it all together, we believe the Tesla story represents the biggest opportunity in tech over the next five years,” Munster said.

Related Links:

Robotics Analyst: Nvidia's AI Developments Don't Change The Self-Driving Car Timeline

The Path Toward Autonomy: Munster On Tesla’s Critical Evolution

A Tesla Model S. Courtesy photo.

Latest Ratings for TSLA

Feb 2019Canaccord GenuityUpgradesHoldBuy
Feb 2019Morgan StanleyMaintainsEqual-WeightEqual-Weight
Jan 2019UBSReiteratesSell

View More Analyst Ratings for TSLA
View the Latest Analyst Ratings

Posted-In: Gene Munster Loup Ventures Model 3 Tesla IncAnalyst Color Analyst Ratings Tech Best of Benzinga


Related Articles (TSLA)

View Comments and Join the Discussion!

Latest Ratings

CBBMorgan StanleyUpgrades10.0
GDCredit SuisseDowngrades184.0
GEOJP MorganDowngrades26.0
TRUERBC CapitalDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mid-Afternoon Market Update: Ocera Therapeutics Surges Following Acquisition News; IMPINJ Shares Plunge

Juno Therapeutics Shows Promise With Non-Hodgkin Lymphoma Drug